Peptides Market Update: Lilly’s $92B Outlook, HHS Peptide Relief, and CagriSema’s 21% Weight Loss

 In Monthly Sector Briefs, Peptide, The Peptide Market, Thematic




Peptide Report · November 2026
A category getting wider in every direction

Eli Lilly grows third quarter revenue 39% to $24.4 billion and raises its 2026 outlook for the third time. Novo Nordisk beats on its Wegovy pill, which brings in DKK 5.39 billion in the quarter, and raises guidance for the third time as well. HHS offers conditional federal enforcement discretion for licensed compounders of six unapproved peptides under an interim policy. And ObesityWeek opens with new CagriSema and retatrutide data. What investors need to know this month.

The two largest peptide drugmakers in the world both raised guidance within a week of each other, and Washington handed the wellness end of the market a policy win in the same stretch. Volume is doing the work at Lilly and Novo, while price keeps falling. The month showed a category getting wider in every direction at once. Here’s the breakdown.







By the Numbers

The Month in Numbers

Lilly Q3

Volume up 53%.
Price down 15%.

Lilly’s third quarter revenue rose 39% on a 53% increase in volume, partly offset by a 15% decline in realized prices.

$24.4BLilly third quarter revenue, up 39%
$91B to $92BLilly’s 2026 revenue outlook
$10.7BMounjaro third quarter sales, up 65%
$5.35BZepbound third quarter sales
$184MFoundayo, Lilly’s new oral drug
DKK 79.2BNovo sales, up 4% at constant exchange rates
5.6MPeople Novo now treats for obesity, with obesity sales up 22%
$842MInsulet third quarter revenue, up 19.2%





Eli Lilly

Lilly Raises Its Outlook a Third Time

Lilly reported on October 29 that third quarter revenue rose 39% to $24.4 billion, ahead of the roughly $22.4 billion analysts expected. It lifted 2026 revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion, its third increase of the year. Mounjaro and Zepbound now make up about two thirds of company revenue. The quarter included about $900 million of one-time benefits, including $410 million of Jardiance milestones.

Our Take

The more important line is volume up 53% against price down 15%. Incretin peptides are moving from a premium product to a mass market one, and the companies winning are the ones that can make enough of them. Lilly also reported head-to-head Phase 3 results for retatrutide against Ozempic and plans to start Phase 3 trials for EloraTZP in the fourth quarter. The pipeline behind tirzepatide is now as large as most companies’ entire businesses.

Oct 29Lilly reports third quarter results.
$24.4BThird quarter revenue, ahead of the roughly $22.4 billion analysts expected.
$91B to $92BNew 2026 revenue guidance, up from $85 billion to $87 billion. The third increase this year.
About 2/3Share of company revenue now coming from Mounjaro and Zepbound.
About $900MOne-time benefits in the quarter, including $410 million of Jardiance milestones.





Novo Nordisk

Novo’s Wegovy Pill Carries the Quarter

DKK 0.00BWegovy pill sales, third quarterAbout $810 million, up 53% from the second quarter and above the DKK 4.62 billion consensus.

Novo reported on November 4 that the Wegovy pill brought in DKK 5.39 billion, about $810 million, up 53% from the second quarter and well above the DKK 4.62 billion consensus. The company raised its 2026 outlook for the third time, now expecting adjusted sales growth of minus 2% to plus 2% at constant exchange rates, up from minus 6% to zero. It is preparing a U.S. launch of CagriSema in early 2027, subject to approval.

Our Take

The weak spot is the injectable. U.S. sales of injectable Wegovy fell 13% at constant exchange rates even as combined U.S. Wegovy sales rose 21%. The pill is largely reaching patients new to GLP-1 obesity treatment rather than simply replacing injectable Wegovy, and that is the right trade. Oral peptides were supposed to be a hard engineering problem. Now one of them is approaching a billion dollars a quarter in its first year on the market.






Policy

HHS Offers Conditional Enforcement Discretion for Six Compounded Peptides

On October 28, HHS released a draft interim policy saying it does not intend to take federal enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound six unapproved peptides, provided its specified conditions are met: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. Pharmacies must meet ten conditions, including a patient-specific prescription, single-ingredient products, lot-level testing and adverse event reporting. The policy is intended to apply to each peptide until FDA issues a final rule on whether it belongs on the 503A bulks list, although HHS may revise it sooner. Public comments closed November 13.

Our Take

None of the six is an FDA-approved drug, and HHS moved ahead despite objections from FDA reviewers. A citizen petition filed October 23 asked the agency to block compounding of these peptides entirely. For investors, the policy matters less for the dollars involved than for what it does to the category. Peptides just gained a higher profile in the wellness market, and every one of these compounded products still needs a pharmaceutical-grade ingredient made by somebody.

Oct 23A citizen petition asks the agency to block compounding of these peptides entirely.
Oct 28HHS releases a draft interim policy on six unapproved peptides.
6 peptidesCovered by the policy, provided its conditions are met.BPC-157TB-500EpitalonSemaxKPVMOTS-c
10 conditionsPharmacies must meet, including patient-specific prescriptions and lot-level testing.
Nov 13Public comments closed.





ObesityWeek

ObesityWeek Raises the Efficacy Bar Again

ObesityWeek opened November 14 in Washington with Novo presenting 26 abstracts. Its Phase 3 REDEFINE 9 trial showed CagriSema at two lower doses produced estimated average weight loss of 20.7% and 21.0% at 68 weeks, against 2.0% on placebo, if patients stayed on treatment. A separate REDEFINE 1 analysis found early responders lost 25% on average. Lilly presented Phase 3 retatrutide data showing reductions in sleep apnea severity and knee osteoarthritis pain.

21.0%CagriSema estimated average weight loss at 68 weeks, one of two lower doses (REDEFINE 9)
20.7%The other lower dose, same trial and timeframe
2.0%Placebo, same trial and timeframe
25%Average loss for early responders (REDEFINE 1 analysis)

REDEFINE 9 figures are estimates that assume patients stayed on treatment.

Our Take

CagriSema pairs a GLP-1 with an amylin analog, two peptides in one injection. Getting 21% weight loss at lower doses could mean fewer side effects and less drug per patient, which matters for manufacturing as much as for patients. The conversation is moving past weight loss alone and into sleep apnea, joint pain and cardiovascular risk, where each new label widens the patient pool.







Company Check-In

Peptide Stocks Making Moves

Beyond the two giants, the month’s moves came from the companies building the next wave of drugs and the devices that deliver them.

VKTXViking Therapeutics

started its Phase 3 SUNRISE program for oral VK2735 on October 14, adding a pill to the two subcutaneous Phase 3 trials already running. It reported a third quarter net loss of $183.2 million and ended September with $960 million in cash, cash equivalents and short-term investments after raising roughly $575 million. Viking presents two VK2735 posters at ObesityWeek.

PODDInsulet

reported third quarter revenue of $842 million, up 19.2%, with international Omnipod sales up 31.7% and adjusted operating margin at 22.0%. It narrowed 2026 guidance to the top of its prior range and authorized a $1 billion buyback. Management also lowered its preliminary 2027 growth outlook and said U.S. new customer starts were flat as new tubeless competitors arrive.







The Bottom Line

What are the key takeaways from the Peptides Market Update?

Lilly at $24.4 billion and guiding to as much as $92 billion. Mounjaro at $10.7 billion in a single quarter. Volume up 53%, price down 15%. The Wegovy pill at $810 million in its first year. Novo raising guidance a third time and lining up CagriSema for early 2027. HHS conditionally declining federal enforcement against compounding of six peptides while FDA reviewers object. CagriSema at 21% on lower doses and retatrutide moving into sleep apnea and joint pain. Viking taking its pill into Phase 3.

The peptide market is no longer one drug class, and the demand is growing faster than the price is falling.

Follow the peptide story every month

Read More REX Insights
Important Information

The Fund is new and has no operating history, and the Index launched on September 24, 2026. No performance is presented in this communication.

The Index’s exposure to peptides may be indirect. Up to 20% of the Index may be allocated to companies that derive less than half of their revenue or research and development activity from peptide-related operations, and constituents may derive significant revenues from broader pharmaceutical, health care, or consumer businesses. The Index’s eligibility screen is a segment and revenue screen, not a guarantee of peptide-related revenue.

An investment in the Fund entails risk, including possible loss of principal. The Fund is not a complete investment program. It is important that investors review the risks below and the risks described in the prospectus, and understand them, before making an investment in the fund.

Investors should consider the investment objectives, risk, charges, and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the REX Peptide ETF please call 1-844-802-4004 or visit our website at rexshares.com. Read the prospectus and summary prospectus carefully before investing.

Important Risks

Peptide Industry Risk. Companies involved in the development, manufacturing, and commercialization of peptide-based products face intense competition, lengthy and uncertain regulatory approval processes, clinical trial failures, patent expirations, pricing and reimbursement pressure, and rapid product obsolescence. Their share prices may be more volatile than the broader market.

Biotechnology, Pharmaceutical, and Health Care Sector Risk. The Fund invests in companies in the biotechnology, pharmaceutical, and health care sectors. These businesses are heavily dependent on government approvals and regulation, patent protection, and the outcome of clinical trials, and can be materially affected by changes in health care policy, drug pricing legislation, supply chain disruption, manufacturing capacity constraints, and product liability claims.

Concentration Risk and Non-Diversification Risk. The Fund concentrates its investments in an industry or group of industries, and as a non-diversified fund it may invest a greater portion of its assets in the securities of a single issuer. Both increase the effect that any single holding or industry development has on the Fund’s value.

Foreign Securities, Currency, Depositary Receipts, Europe and Asia Risk. The Fund invests significantly in securities of non-US issuers, directly and through depositary receipts. Foreign investments involve risks not typically associated with US investments, including currency fluctuation, different regulatory and accounting standards, less liquidity, higher transaction costs, and political and economic developments specific to a country or region. The Index may have significant exposure to Europe and Asia.

New Fund, New Index, Index Provider, Passive Investment and Non-Correlation Risk. The Fund is recently organized and has no operating history. The Index is newly created and has a limited history. The Fund is not actively managed and relies on the Index Provider’s methodology and data; errors in index construction or calculation may not be identified or corrected promptly. The Fund’s return may not match the Index’s return.

Equity, Large, Mid and Small Capitalization, Liquidity, Volatility, Trading Issues, Premium/Discount, Costs of Buying and Selling Fund Shares, Authorized Participant and Operational Risk. Equity values rise and fall. Smaller companies may be more volatile and less liquid than larger companies. Shares may trade at a premium or discount to net asset value, trading may be halted, and the Fund relies on a limited number of authorized participants and market makers. Buying and selling shares involves brokerage and other costs.

Total annual fund operating expenses are 0.65%. The Adviser pays all Fund expenses excluding the management fee, interest, taxes, acquired fund fees and expenses, and brokerage commissions. See the prospectus for the full fee table, the investment objective, and complete risk disclosures. The Fund is a series of REX ETF Trust. The Fund’s investment adviser is REX Advisers, LLC.

The VettaFi Peptide Index is a service mark of VettaFi LLC and has been licensed for use by REX Shares, LLC and the REX Peptide ETF. The REX Peptide ETF is not sponsored, endorsed, sold or promoted by VettaFi LLC and VettaFi LLC makes no representation regarding the advisability of investing in the REX Peptide ETF.

Distributor: Foreside Fund Services, LLC, member FINRA, not affiliated with REX Shares or the Fund’s investment advisor.